Dr. Lawrence A. Zumo

Pavel Klein is a Neurologist practicing medicine in Bethesda, Maryland. Dr. Klein is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Seizures, Epilepsy, Generalized Tonic-Clonic Seizure, and Absence Seizure. Dr. Klein is currently accepting new patients.

Fernando Pagan is a Neurologist practicing medicine in Washington, Washington, D.c.. Dr. Pagan is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Lewy Body Dementia (LBD), Benign Essential Blepharospasm, and Deep Brain Stimulation.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy. Dr. Blakeley is board certified in American Board Of Psychiatry And Neurology. Dr. Blakeley is currently accepting new patients.